Top Tweets for #OAOnTheGo
🎥 #OAOnTheGo | #ESMO26 🇪🇸in Portuguese for our 🇧🇷 🇵🇹 Colleagues
Dr. Guilherme Andriatte @guiandri76 🇧🇷 (Einstein, São Paulo) comenta o iza-bren no câncer de mama metastático RH+/HER2− 🔑
ADC biespecífico anti-EGFR/HER3 vs QT de escolha do investigador, após iCDK e QT prévia:
📊 SLP: 8 vs 4 meses (HR 0,4)
📊 Sem progressão em 1 ano: ~20% vs 9%
⚠️ Atenção às citopenias
Como fica frente a T-DXd e Dato-DXd? 👇
Pinging OncoAlert #BreastCancer Faculty
@matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @aftimosp @kevinpunie @ElisaAgostinett @to_be_elizabeth @GaiaGriguolo @JankovicK @raalbany @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @LoiSher @jamecancerdoc
@Lucarecco @Dr_Oncologista
The @OncoAlert #OAOnTheGO straight from #ESMO26 🇪🇸
Really important discussion on de-escalation in older women with low-risk early breast cancer.
Great breakdown by our collegue Dr. Elisabetta Bonzano @to_be_elizabeth Looking forward to more data from EUROPA
The OncoAlert #OAOnTheGO straight from #ESMO26
Can we omit BOTH radiotherapy and endocrine therapy after breast-conserving surgery in older women with low-risk early breast cancer? 🤔
Our Faculty Dr. Elisabetta Bonzano🇮🇹 breaks down the TOP-1 trial for OncoAlert:
🔹 792 patients, age >70, HR+/HER2−, 75% grade 1
🔹 5-year local recurrence: nearly 15%, despite careful selection
🔹 Breast cancer–specific survival remains excellent, but recurrences still mean more surgery and treatment
De-escalation means balancing local control, survival and quality of life. EUROPA (RT alone vs ET alone) will add to the picture. . #BreastCancer
Pinging OncoAlert Breast Cancer Faculty
@matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @aftimosp @kevinpunie @ElisaAgostinett @to_be_elizabeth @GaiaGriguolo @JankovicK @raalbany @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @LoiSher @jamecancerdoc
@Lucarecco @Dr_Oncologista @guiandri76
🎥 #OAOnTheGo | #ESMO26 🇪🇸 in Portuguese for our 🇧🇷 🇵🇹 Colleagues
Dr. Miguel Zugman @mzugman (Einstein, São Paulo) comenta o DASL-HiCaP 🔑
Câncer de próstata localizado de muito alto risco:
RT + ADT + darolutamida vs placebo por 2 anos
📊 MFS em 4 anos: 95% vs 88%
✅ Também positivo em sobrevida livre de progressão de PSA
⏳ SG ainda imatura
Dados muito promissores 👇
#CâncerDePróstata #OncoAlert #GUOnc
Pinging Our Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper @Markuseckstein3
🚨 Practice-changing in ES-SCLC? #ESMO26
Dr. Uğur Özkerim 🇹🇷 breaks down phase 3 DeLLphi-305 for #OAOnTheGo in Madrid. Presented by @sands_jacob and Simultaneously published in @NEJM.
Maintenance after 1L chemo-IO:
🔹 Tarlatamab + durvalumab vs durvalumab alone
🔹 Median OS: 21 vs 13 months
🔹 PFS also significantly improved
⚠️ Neurological toxicity needs close monitoring
🎥 👇 #OncoAlert #LungCancer #SCLC
Pinging our faculty
@christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @jillfeldman4, @UOzkerim, @DrMirallas, @MartinReck2 , @bmassutis @UmbertoMalapel1 , @CharuAggarwalMD
@peters_solange, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @VanitaNoronha, @ChristianRolfo @Tony_Calles @s_couraud @marinagarassino @g_mountzios @BairdAM @barlesi @JFreemanDaily @Piuchagarrido @PercyLeeMD @bensolomon1 @VanitaNoronha @alexdrilon @JordiRemon @JulienMazieres @TerriConneran @HenningWillers
The OncoAlert #OAOnTheGO straight from #ESMO26
Can we omit BOTH radiotherapy and endocrine therapy after breast-conserving surgery in older women with low-risk early breast cancer? 🤔
Our Faculty Dr. Elisabetta Bonzano🇮🇹 breaks down the TOP-1 trial for OncoAlert:
🔹 792 patients, age >70, HR+/HER2−, 75% grade 1
🔹 5-year local recurrence: nearly 15%, despite careful selection
🔹 Breast cancer–specific survival remains excellent, but recurrences still mean more surgery and treatment
De-escalation means balancing local control, survival and quality of life. EUROPA (RT alone vs ET alone) will add to the picture. . #BreastCancer
Pinging OncoAlert Breast Cancer Faculty
@matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @aftimosp @kevinpunie @ElisaAgostinett @to_be_elizabeth @GaiaGriguolo @JankovicK @raalbany @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @LoiSher @jamecancerdoc
@Lucarecco @Dr_Oncologista @guiandri76
🎥 #OAOnTheGO | #ESMO26 Madrid
@OncoAlert
Personalized cancer vaccination is moving from concept to clinically meaningful signal.
INTerpath-001 is positive.
Dr. @MarioBalsaMD discusses pembrolizumab + personalized mRNA vaccine V940 in resected #Melanoma.
📊 2-year RFS: 82% vs 60%
HR 0.58
📊 DMFS: 88.5% vs 80.2%
HR 0.62
🎯 Why this matters: this is not simply another adjuvant immunotherapy study. It is a proof-of-concept that a patient-specific neoantigen vaccine can add meaningful disease-control benefit to PD-1 blockade.
For me, the next questions are even more important:
🧬 Who benefits most?
⏳ Will this translate into an OS advantage?
🔄 How should it be positioned relative to neoadjuvant immunotherapy?
🎯 Can biomarkers identify the patients who truly need this degree of personalization?
Excellent discussion by @MarioBalsaMD, building on important work from @ProfGLongMIA @jasonlukemd and the INTerpath-001 investigators.
🎬 Watch the latest #OAOnTheGO from @OncoAlert.
@DrBetofMDPhD @cdanicas @UOzkerim @DrMirallas @DrYukselUrun @GaiaGriguolo @JankovicK @ElisaAgostinett @to_be_elizabeth @nataliagandur
#OncoAlert #ESMO26 #Melanoma #mRNA #CancerVaccines #Immunotherapy #PrecisionOncology
🎥 #OAOnTheGO | OncoAlert at #ESMO26 Madrid
INTerpath-001 is positive! 🔬
@ProfGLongMIA @jasonlukemd
Dr. Mario Balsa (@HospitalClínic Barcelona) discusses pembrolizumab + personalized mRNA vaccine V940 in resected melanoma.
📊 2-year RFS: 82% vs 60% (HR 0.58)
📊 DMFS: 88.5% vs 80.2% (HR 0.62)
Will this translate into longer survival? Who benefits most? And how does it fit with neoadjuvant immunotherapy?
🎬 Watch now!
#Melanoma #OncoAlert
@DrBetofMDPhD, @cdanicas, @matteolambe, @NiuSanford, @GlopesMd, @PGrivasMDPhD, @brian_rini, @to_be_elizabeth, @ElisaAgostinett, @nataliagandur, @UOzkerim, @DrMirallas, @DrYukselUrun, @Lucarecco, @mzugman, @HHorinouchi, @p_ciracimd, @DraMartinezLago, @DrVilmaPBarcia, @GIMedOnc, @MarioBalsaMD, @scocmem, @AmandaNizamMD, @GaiaGriguolo, @JankovicK, @Dr_Oncologista, @Erman_Akkus, @WeOncologists, @niklas_kluemper, @Markuseckstein
🎥 #OAOnTheGO | #ESMO26 Madrid
@OncoAlert
The most interesting part of the 6-year NATALEE update is not only that the benefit persists — it is that the gap in invasive disease-free survival continues to widen after ribociclib has stopped.
Dr. Gil Morgan @OncoAlert breaks down the new data:
📊 OS: HR 0.81
➡️ 2.1% absolute benefit at 6 years
📊 iDFS: absolute benefit now 5.3%
✅ No new safety signals
⏳ Patients are now more than 3 years off ribociclib
🎯 Why this matters: adjuvant therapy asks patients to accept treatment and toxicity today for a benefit that may only become fully visible years later.
For me, the key question is whether the widening reduction in recurrence will ultimately translate into a durable survival advantage with longer follow-up.
The OS analysis remains descriptive and the absolute difference is still modest — but this is exactly why mature follow-up matters.
🎬 Watch Dr. Gil Morgan’s clinical take in the latest #OAOnTheGO from @OncoAlert.
@matteolambe @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @kevinpunie @GaiaGriguolo @JankovicK @LoiSher
#BreastCancer #NATALEE #Ribociclib #CDK46 #AdjuvantTherapy #OncoAlert
🎥 #OAOnTheGO Series in| #ESMO26 Madrid
Dr. Gil Morgan (@OncoAlert) breaks down the 6-year NATALEE update!
In this episode of #OAOnTheGO, Dr. Gil Morgan, OncoAlert representative, breaks down the 6-year NATALEE update, simultaneously published in Annals of Oncology.
🔬 Key takeaways:
📊 Overall survival: HR 0.81, with a 2.1% absolute benefit at 6 years.
📊 Invasive disease-free survival: Absolute benefit has widened to 5.3%.
📊 No new safety signals, with patients now more than 3 years off ribociclib.
These findings strengthen the role of adjuvant ribociclib for eligible patients with high-risk, HR-positive, HER2-negative early breast cancer.
While the overall survival analysis remains descriptive and the absolute benefit is modest, the results bring an important question into focus: Can preventing more recurrences ultimately help more patients live longer?
🎬 Watch Dr. Gil Morgan's clinical take in the latest #OAOnTheGO by OncoAlert.
Pinging OncoAlert Breast Cancer Faculty
@matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @aftimosp @kevinpunie @ElisaAgostinett @to_be_elizabeth @GaiaGriguolo @JankovicK @raalbany @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @LoiSher @jamecancerdoc
@Lucarecco @Dr_Oncologista @guiandri76
🎥 #OAOnTheGO from #ESMO26 🇪🇸
Great breakdown by Dr. Gil Morgan @weoncologists on the 6-year NATALEE update.
@OncoAlert @myESMO #BreastCancer
🎥 #OAOnTheGO Series in| #ESMO26 Madrid
Dr. Gil Morgan (@OncoAlert) breaks down the 6-year NATALEE update!
In this episode of #OAOnTheGO, Dr. Gil Morgan, OncoAlert representative, breaks down the 6-year NATALEE update, simultaneously published in Annals of Oncology.
🔬 Key takeaways:
📊 Overall survival: HR 0.81, with a 2.1% absolute benefit at 6 years.
📊 Invasive disease-free survival: Absolute benefit has widened to 5.3%.
📊 No new safety signals, with patients now more than 3 years off ribociclib.
These findings strengthen the role of adjuvant ribociclib for eligible patients with high-risk, HR-positive, HER2-negative early breast cancer.
While the overall survival analysis remains descriptive and the absolute benefit is modest, the results bring an important question into focus: Can preventing more recurrences ultimately help more patients live longer?
🎬 Watch Dr. Gil Morgan's clinical take in the latest #OAOnTheGO by OncoAlert.
Pinging OncoAlert Breast Cancer Faculty
@matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @aftimosp @kevinpunie @ElisaAgostinett @to_be_elizabeth @GaiaGriguolo @JankovicK @raalbany @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @LoiSher @jamecancerdoc
@Lucarecco @Dr_Oncologista @guiandri76
Encouraging long-term results from NATALEE! 👏
The growing iDFS benefit and emerging OS signal are promising for patients with HR+/HER2− early breast cancer.
Great insights from Dr. Gil Morgan and a fantastic way to share the latest updates through the #OAOnTheGo series! 👏 #ESMO26
🎥 #OAOnTheGO Series in| #ESMO26 Madrid
Dr. Gil Morgan (@OncoAlert) breaks down the 6-year NATALEE update!
In this episode of #OAOnTheGO, Dr. Gil Morgan, OncoAlert representative, breaks down the 6-year NATALEE update, simultaneously published in Annals of Oncology.
🔬 Key takeaways:
📊 Overall survival: HR 0.81, with a 2.1% absolute benefit at 6 years.
📊 Invasive disease-free survival: Absolute benefit has widened to 5.3%.
📊 No new safety signals, with patients now more than 3 years off ribociclib.
These findings strengthen the role of adjuvant ribociclib for eligible patients with high-risk, HR-positive, HER2-negative early breast cancer.
While the overall survival analysis remains descriptive and the absolute benefit is modest, the results bring an important question into focus: Can preventing more recurrences ultimately help more patients live longer?
🎬 Watch Dr. Gil Morgan's clinical take in the latest #OAOnTheGO by OncoAlert.
Pinging OncoAlert Breast Cancer Faculty
@matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @aftimosp @kevinpunie @ElisaAgostinett @to_be_elizabeth @GaiaGriguolo @JankovicK @raalbany @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @LoiSher @jamecancerdoc
@Lucarecco @Dr_Oncologista @guiandri76
📌#OAOnTheGO 🎥 | OncoAlert at #ESMO26 Madrid
INTerpath-001 is positive! 🔬
@ProfGLongMIA @jasonlukemd
Dr. Mario Balsa (@HospitalClínic Barcelona) discusses pembrolizumab + personalized mRNA vaccine V940 in resected melanoma.
📊 2-year RFS: 82% vs 60% (HR 0.58)
📊 DMFS: 88.5% vs 80.2% (HR 0.62)
Will this translate into longer survival? Who benefits most? And how does it fit with neoadjuvant immunotherapy?
🎬 Watch now!
🎥 #OAOnTheGO | OncoAlert at #ESMO26 Madrid
INTerpath-001 is positive! 🔬
@ProfGLongMIA @jasonlukemd
Dr. Mario Balsa (@HospitalClínic Barcelona) discusses pembrolizumab + personalized mRNA vaccine V940 in resected melanoma.
📊 2-year RFS: 82% vs 60% (HR 0.58)
📊 DMFS: 88.5% vs 80.2% (HR 0.62)
Will this translate into longer survival? Who benefits most? And how does it fit with neoadjuvant immunotherapy?
🎬 Watch now!
#Melanoma #OncoAlert
@DrBetofMDPhD, @cdanicas, @matteolambe, @NiuSanford, @GlopesMd, @PGrivasMDPhD, @brian_rini, @to_be_elizabeth, @ElisaAgostinett, @nataliagandur, @UOzkerim, @DrMirallas, @DrYukselUrun, @Lucarecco, @mzugman, @HHorinouchi, @p_ciracimd, @DraMartinezLago, @DrVilmaPBarcia, @GIMedOnc, @MarioBalsaMD, @scocmem, @AmandaNizamMD, @GaiaGriguolo, @JankovicK, @Dr_Oncologista, @Erman_Akkus, @WeOncologists, @niklas_kluemper, @Markuseckstein
📌 #OAOnTheGO Series 🎥 in| #ESMO26 Madrid
Dr. Gil Morgan (@OncoAlert) breaks down the 6-year NATALEE update!
In this episode of #OAOnTheGO, Dr. Gil Morgan, OncoAlert representative, breaks down the 6-year NATALEE update, simultaneously published in Annals of Oncology.
🎥 #OAOnTheGO Series in| #ESMO26 Madrid
Dr. Gil Morgan (@OncoAlert) breaks down the 6-year NATALEE update!
In this episode of #OAOnTheGO, Dr. Gil Morgan, OncoAlert representative, breaks down the 6-year NATALEE update, simultaneously published in Annals of Oncology.
🔬 Key takeaways:
📊 Overall survival: HR 0.81, with a 2.1% absolute benefit at 6 years.
📊 Invasive disease-free survival: Absolute benefit has widened to 5.3%.
📊 No new safety signals, with patients now more than 3 years off ribociclib.
These findings strengthen the role of adjuvant ribociclib for eligible patients with high-risk, HR-positive, HER2-negative early breast cancer.
While the overall survival analysis remains descriptive and the absolute benefit is modest, the results bring an important question into focus: Can preventing more recurrences ultimately help more patients live longer?
🎬 Watch Dr. Gil Morgan's clinical take in the latest #OAOnTheGO by OncoAlert.
Pinging OncoAlert Breast Cancer Faculty
@matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @aftimosp @kevinpunie @ElisaAgostinett @to_be_elizabeth @GaiaGriguolo @JankovicK @raalbany @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @LoiSher @jamecancerdoc
@Lucarecco @Dr_Oncologista @guiandri76
🎥 #OAOnTheGO Series in| #ESMO26 Madrid
Dr. Gil Morgan (@OncoAlert) breaks down the 6-year NATALEE update!
In this episode of #OAOnTheGO, Dr. Gil Morgan, OncoAlert representative, breaks down the 6-year NATALEE update, simultaneously published in Annals of Oncology.
🔬 Key takeaways:
📊 Overall survival: HR 0.81, with a 2.1% absolute benefit at 6 years.
📊 Invasive disease-free survival: Absolute benefit has widened to 5.3%.
📊 No new safety signals, with patients now more than 3 years off ribociclib.
These findings strengthen the role of adjuvant ribociclib for eligible patients with high-risk, HR-positive, HER2-negative early breast cancer.
While the overall survival analysis remains descriptive and the absolute benefit is modest, the results bring an important question into focus: Can preventing more recurrences ultimately help more patients live longer?
🎬 Watch Dr. Gil Morgan's clinical take in the latest #OAOnTheGO by OncoAlert.
Pinging OncoAlert Breast Cancer Faculty
@matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @aftimosp @kevinpunie @ElisaAgostinett @to_be_elizabeth @GaiaGriguolo @JankovicK @raalbany @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @LoiSher @jamecancerdoc
@Lucarecco @Dr_Oncologista @guiandri76
🎥 #OAOnTheGO | OncoAlert at #ESMO26 Madrid
INTerpath-001 is positive! 🔬
@ProfGLongMIA @jasonlukemd
Dr. Mario Balsa (@HospitalClínic Barcelona) discusses pembrolizumab + personalized mRNA vaccine V940 in resected melanoma.
📊 2-year RFS: 82% vs 60% (HR 0.58)
📊 DMFS: 88.5% vs 80.2% (HR 0.62)
Will this translate into longer survival? Who benefits most? And how does it fit with neoadjuvant immunotherapy?
🎬 Watch now!
#Melanoma #OncoAlert
@DrBetofMDPhD, @cdanicas, @matteolambe, @NiuSanford, @GlopesMd, @PGrivasMDPhD, @brian_rini, @to_be_elizabeth, @ElisaAgostinett, @nataliagandur, @UOzkerim, @DrMirallas, @DrYukselUrun, @Lucarecco, @mzugman, @HHorinouchi, @p_ciracimd, @DraMartinezLago, @DrVilmaPBarcia, @GIMedOnc, @MarioBalsaMD, @scocmem, @AmandaNizamMD, @GaiaGriguolo, @JankovicK, @Dr_Oncologista, @Erman_Akkus, @WeOncologists, @niklas_kluemper, @Markuseckstein
🧬 Can triplet combinations improve outcomes in advanced urothelial cancer? And how do we manage their toxicity? #OAOnTheGo Series
In this new OncoAlert video live from the floor at #ESMO26, Dr. Sara Coca Membribes, @scocmem medical oncologist and genitourinary (GU) clinical research fellow at the Barts Cancer Institute🇬🇧 , discusses the results of TROPHY Cohort 7, evaluating sacituzumab govitecan (SG), enfortumab vedotin (EV), and a PD-1 inhibitor. @OncoAlert
🧬 Can triplet combinations improve outcomes in advanced urothelial cancer? And how do we manage their toxicity? #OAOnTheGo Series
In this new OncoAlert video live from the floor at #ESMO26, Dr. Sara Coca Membribes, @scocmem medical oncologist and genitourinary (GU) clinical research fellow at the Barts Cancer Institute🇬🇧 , discusses the results of TROPHY Cohort 7, evaluating sacituzumab govitecan (SG), enfortumab vedotin (EV), and a PD-1 inhibitor.
🔬 Key takeaways:
▪️ All 18 patients achieved tumor shrinkage, with durable responses.
▪️ No treatment-related deaths were reported.
▪️ Approximately 60% of patients experienced Grade 3 adverse events.
▪️ G-CSF support was mandatory in the study.
With several trials exploring frontline triplet combinations using different ADCs, payloads, and targeted therapies—including FGFR3 inhibition in the FORAGER trial—the challenge is not only achieving efficacy, but also managing toxicity without compromising treatment outcomes.
🎥 Watch Dr. Sara Coca Membribes' video for her insights into these promising strategies and why toxicity management is essential for the future of combination therapy.
#UrothelialCancer #BladderCancer
Pinging Our Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper @Markuseckstein3
🎬 New #OAOnTheGo 🎥 from #ESMO26 @OncoAlert
Our #OncoAlertAF colleagues & Melanoma specialist Dr. @MarioBalsaMD (Hospital Clínic Barcelona) on treating patients who don’t fit the trials:
🤰 Melanoma in pregnancy: very limited data, and none at all for anti-LAG3
Transplant recipients: checkpoint inhibitors can work, but rejection occurs in ~1 in 3
Immunotherapy is never just about the tumor 👇
🎬 New #OAOnTheGo 🎥 from #ESMO26
Our #OncoAlertAF colleagues & Melanoma specialist Dr. @MarioBalsaMD (Hospital Clínic Barcelona) on treating patients who don’t fit the trials:
🤰 Melanoma in pregnancy: very limited data, and none at all for anti-LAG3
Transplant recipients: checkpoint inhibitors can work, but rejection occurs in ~1 in 3
Immunotherapy is never just about the tumor 👇
#ESMO26 #Melanoma
@DrBetofMDPhD @cdanicas, @matteolambe, @NiuSanford, @GlopesMd, @PGrivasMDPhD, @brian_rini, @to_be_elizabeth, @ElisaAgostinett, @nataliagandur, @UOzkerim, @DrMirallas, @DrYukselUrun, @Lucarecco, @mzugman, @HHorinouchi, @p_ciracimd, @DraMartinezLago, @DrVilmaPBarcia, @GIMedOnc, @MarioBalsaMD, @scocmem, @AmandaNizamMD, @GaiaGriguolo, @JankovicK, @Dr_Oncologista, @Erman_Akkus, @WeOncologists, @niklas_kluemper, @Markuseckstein
🎬 Loved kicking off #OAOnTheGo at #ESMO26 with a topic that rarely fits neatly into trial eligibility criteria!
Pregnancy, transplantation, immunosuppression…the hardest part of immunotherapy is understanding the patient around it!
Thanks @OncoAlert for everything! 🖤
@OncoReporte @myESMO @_SEOM @GrupoMelanoma
@hospitalclinic
#ClínicBarcelonaComprehensiveCancerCenter
🎬 New #OAOnTheGo 🎥 from #ESMO26
Our #OncoAlertAF colleagues & Melanoma specialist Dr. @MarioBalsaMD (Hospital Clínic Barcelona) on treating patients who don’t fit the trials:
🤰 Melanoma in pregnancy: very limited data, and none at all for anti-LAG3
Transplant recipients: checkpoint inhibitors can work, but rejection occurs in ~1 in 3
Immunotherapy is never just about the tumor 👇
#ESMO26 #Melanoma
@DrBetofMDPhD @cdanicas, @matteolambe, @NiuSanford, @GlopesMd, @PGrivasMDPhD, @brian_rini, @to_be_elizabeth, @ElisaAgostinett, @nataliagandur, @UOzkerim, @DrMirallas, @DrYukselUrun, @Lucarecco, @mzugman, @HHorinouchi, @p_ciracimd, @DraMartinezLago, @DrVilmaPBarcia, @GIMedOnc, @MarioBalsaMD, @scocmem, @AmandaNizamMD, @GaiaGriguolo, @JankovicK, @Dr_Oncologista, @Erman_Akkus, @WeOncologists, @niklas_kluemper, @Markuseckstein
🎬New #OAOnTheGo from #ESMO26 🇪🇸
Our #OncoAlertAF collegue Dr
@MarioBalsaMD 🇪🇸 on treating #melanoma patients who don’t fit the trials 👇 @OncoAlert
🎬 New #OAOnTheGo 🎥 from #ESMO26
Our #OncoAlertAF colleagues & Melanoma specialist Dr. @MarioBalsaMD (Hospital Clínic Barcelona) on treating patients who don’t fit the trials:
🤰 Melanoma in pregnancy: very limited data, and none at all for anti-LAG3
Transplant recipients: checkpoint inhibitors can work, but rejection occurs in ~1 in 3
Immunotherapy is never just about the tumor 👇
#ESMO26 #Melanoma
@DrBetofMDPhD @cdanicas, @matteolambe, @NiuSanford, @GlopesMd, @PGrivasMDPhD, @brian_rini, @to_be_elizabeth, @ElisaAgostinett, @nataliagandur, @UOzkerim, @DrMirallas, @DrYukselUrun, @Lucarecco, @mzugman, @HHorinouchi, @p_ciracimd, @DraMartinezLago, @DrVilmaPBarcia, @GIMedOnc, @MarioBalsaMD, @scocmem, @AmandaNizamMD, @GaiaGriguolo, @JankovicK, @Dr_Oncologista, @Erman_Akkus, @WeOncologists, @niklas_kluemper, @Markuseckstein
🎬 New #OAOnTheGo 🎥 from #ESMO26
Our #OncoAlertAF colleagues & Melanoma specialist Dr. @MarioBalsaMD (Hospital Clínic Barcelona) on treating patients who don’t fit the trials:
🤰 Melanoma in pregnancy: very limited data, and none at all for anti-LAG3
Transplant recipients: checkpoint inhibitors can work, but rejection occurs in ~1 in 3
Immunotherapy is never just about the tumor 👇
#ESMO26 #Melanoma
@DrBetofMDPhD @cdanicas, @matteolambe, @NiuSanford, @GlopesMd, @PGrivasMDPhD, @brian_rini, @to_be_elizabeth, @ElisaAgostinett, @nataliagandur, @UOzkerim, @DrMirallas, @DrYukselUrun, @Lucarecco, @mzugman, @HHorinouchi, @p_ciracimd, @DraMartinezLago, @DrVilmaPBarcia, @GIMedOnc, @MarioBalsaMD, @scocmem, @AmandaNizamMD, @GaiaGriguolo, @JankovicK, @Dr_Oncologista, @Erman_Akkus, @WeOncologists, @niklas_kluemper, @Markuseckstein
🚨 In urothelial cancer, the next frontier may be triplets — but efficacy will only matter if we can actually deliver them safely.
@OncoAlert @myESMO
In a new #OAOnTheGo video from #ESMO26, @scocmem discusses TROPHY Cohort 7, evaluating sacituzumab govitecan + enfortumab vedotin + PD-1 blockade in advanced #UrothelialCancer.
The activity is striking:
🔹 All 18 patients had tumor shrinkage
🔹 Responses were durable
🔹 No treatment-related deaths
🔹 But ~60% experienced grade 3 AEs
🔹 G-CSF support was mandatory
🎯 Why this matters: combining ADCs with different targets and payloads may deepen responses — but the therapeutic window becomes the real challenge.
For me, the key question is no longer simply:
“Can triplets work?”
It is:
“Can we identify the patients who need this degree of intensification, choose complementary mechanisms, and proactively manage toxicity well enough to preserve the benefit?”
With other frontline triplet strategies emerging — including biomarker-driven approaches such as FGFR3 inhibition in FORAGER — this balance between depth of response and treatment burden will be critical.
Excellent insights from @scocmem.
@PGrivasMDPhD @tompowles1 @AndreaNecchi @apolo_andrea @niklas_kluemper @Markuseckstein3 @shilpaonc @DrYukselUrun @crisbergerot @nataliagandur
#OncoAlert #ESMO26 #BladderCancer #ADC #EV #SacituzumabGovitecan #PrecisionOncology
🧬 Can triplet combinations improve outcomes in advanced urothelial cancer? And how do we manage their toxicity? #OAOnTheGo Series
In this new OncoAlert video live from the floor at #ESMO26, Dr. Sara Coca Membribes, @scocmem medical oncologist and genitourinary (GU) clinical research fellow at the Barts Cancer Institute🇬🇧 , discusses the results of TROPHY Cohort 7, evaluating sacituzumab govitecan (SG), enfortumab vedotin (EV), and a PD-1 inhibitor.
🔬 Key takeaways:
▪️ All 18 patients achieved tumor shrinkage, with durable responses.
▪️ No treatment-related deaths were reported.
▪️ Approximately 60% of patients experienced Grade 3 adverse events.
▪️ G-CSF support was mandatory in the study.
With several trials exploring frontline triplet combinations using different ADCs, payloads, and targeted therapies—including FGFR3 inhibition in the FORAGER trial—the challenge is not only achieving efficacy, but also managing toxicity without compromising treatment outcomes.
🎥 Watch Dr. Sara Coca Membribes' video for her insights into these promising strategies and why toxicity management is essential for the future of combination therapy.
#UrothelialCancer #BladderCancer
Pinging Our Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper @Markuseckstein3
This is exactly why I love @OncoAlert’s #OAOnTheGo!!!!
@scocmem breaks down TROPHY Cohort 7 brilliantly! Impressive activity, but without losing sight of the real issue: how much toxicity are we willing to accept for more efficacy?
Clear, sharp, clinically relevant! 👏🏼 Sara absolutely nails it!
@myESMO
🧬 Can triplet combinations improve outcomes in advanced urothelial cancer? And how do we manage their toxicity? #OAOnTheGo Series
In this new OncoAlert video live from the floor at #ESMO26, Dr. Sara Coca Membribes, @scocmem medical oncologist and genitourinary (GU) clinical research fellow at the Barts Cancer Institute🇬🇧 , discusses the results of TROPHY Cohort 7, evaluating sacituzumab govitecan (SG), enfortumab vedotin (EV), and a PD-1 inhibitor.
🔬 Key takeaways:
▪️ All 18 patients achieved tumor shrinkage, with durable responses.
▪️ No treatment-related deaths were reported.
▪️ Approximately 60% of patients experienced Grade 3 adverse events.
▪️ G-CSF support was mandatory in the study.
With several trials exploring frontline triplet combinations using different ADCs, payloads, and targeted therapies—including FGFR3 inhibition in the FORAGER trial—the challenge is not only achieving efficacy, but also managing toxicity without compromising treatment outcomes.
🎥 Watch Dr. Sara Coca Membribes' video for her insights into these promising strategies and why toxicity management is essential for the future of combination therapy.
#UrothelialCancer #BladderCancer
Pinging Our Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper @Markuseckstein3
Last Seen Hashtags on Sotwe
minichatt()***************** filter:videos
Seen from Peru
انطونيو_مع_انجي_خوري
Seen from Egypt
hardcore
Seen from Canada
minichat video*
Seen from Turkey
lockerroom gay
Seen from Chile
anxiouspanda()*********** filter:native_video
Seen from United Kingdom
femboy asian cd
Seen from United States
FuentesdeBéjar
Seen from United States
CaughtOnCamera
Seen from Germany
vestiario
Seen from Brazil
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.5M followers
Barack Obama
@barackobama
118.8M followers
Cristiano Ronaldo
@cristiano
114.5M followers
Donald J. Trump
@realdonaldtrump
111.9M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.3M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90M followers
Taylor Swift
@taylorswift13
84M followers
Lady Gaga
@ladygaga
75.5M followers
Virat Kohli
@imvkohli
73.5M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.5M followers
Bill Gates
@billgates
65.3M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.2M followers
CNN
@cnn
61.7M followers
X
@x
60.7M followers